Bausch Health Companies Inc. (BHC)
Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - Specialty & Generic
Bausch Health Companies Inc.
- 2.8%
- 7.4M
- 1.24
Float 264.25M · Market-data free float · Oct 2, 2026
The cost to borrow BHC shares for a short sale and how many shares are available to borrow, refreshed through the session.
- 36.5%
- 38.9K
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 7.4M sh |
| Oct 15, 2026 | 8.2M sh |
| Sep 30, 2026 | 8.4M sh |
| Sep 15, 2026 | 8.6M sh |
| Aug 31, 2026 | 8.2M sh |
Latest fails to deliver
| Date | Shares failed |
|---|---|
| Oct 30, 2026 | 38.9K sh |
| Oct 29, 2026 | 78.5K sh |
| Oct 27, 2026 | 1.0K sh |
| Oct 23, 2026 | 1.2K sh |
| Oct 22, 2026 | 113.4K sh |
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 18, 2026 | 36.5% |
| Nov 17, 2026 | 22.2% |
| Nov 16, 2026 | 34.4% |
| Nov 13, 2026 | 45.3% |
| Nov 12, 2026 | 37.0% |
130 calendar days requested; 92 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for BHC: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 7,409,975 BHC shares were sold short (2.80% of a 264.25M-share float, 1.24 days to cover).